Houston hospitals got their report cards. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Close to half of the Houston area's general acute-care hospitals are at the top of their class, according to new safety grades assigned to U.S. hospitals. But one hospital in the region is failing on the safety front, the grades show.

In its fall 2019 report card for acute-care hospitals, The Leapfrog Group gives letter grades of A, B, C, D, and F based on the hospitals' ability to shield patients from avoidable errors, injuries, accidents, and infections. The nonprofit represents hundreds of public and private employers that buy healthcare benefits.

In the Houston area, 19 hospitals earned an A, with 14 receiving a B, seven getting a C, one picking up a D and one being slapped with an F.

Chris Skisak, executive director of the Houston Business Coalition on Health, notes that 23 percent of hospitals in the Houston areas saw their Leapfrog grades go up while just 11 percent saw their grades go down. The coalition is a regional leader for The Leapfrog Group.

"Houston-area hospitals do care about their grades," Skisak says, "and going back to 2016, most obtained a higher grade after receiving a lower grade the previous assessment period. Houston is fortunate to have [about] 50 percent of its hospitals earn consistent A grades."

For the first time in at least four years, The Leapfrog Group did hit one Houston-area hospital — Huntsville Memorial Hospital — with an F. On the spring 2019 report card, the hospital received a D. In the fall of 2018, the mark was a C.

Huntsville Memorial Hospital currently is combating what's been described as a "dire financial situation."

In a November 1 statement, the Walker County Hospital District, which owns the Huntsville hospital, said the separate nonprofit entity that runs the hospital — Walker County Hospital Corp. — was beset by monetary woes and was on the verge of declaring Chapter 11 bankruptcy. As a result, the district warned, the hospital might close.

According to The Huntsville Item, a proposed rescue of the hospital would place ownership and management in the hands of a joint venture between the hospital district and Plano-based Community Hospital Corp., a hospital management company. The nonprofit Plano company provides supply-chain services to a Huntsville medical practice, Huntsville Orthopedic Surgery and Sports Medicine PLLC.

In the statement, the district's board says it "remains committed to maintaining a viable hospital for the community and to improving hospital operations and services."

The Leapfrog Group graded a total of 42 hospitals in the Houston area. The nonprofit released its fall 2019 report card on November 7.

Houston-area hospitals that earned an A were:

  • Houston Methodist Baytown Hospital
  • HCA Houston Healthcare Conroe
  • HCA Houston Healthcare West
  • Houston Methodist Hospital
  • Houston Methodist West Hospital
  • Houston Methodist Willowbrook Hospital
  • Memorial Hermann Southeast
  • Memorial Hermann Southwest Hospital
  • Memorial Hermann Northeast, Humble
  • Memorial Hermann Katy Hospital
  • HCA Houston Healthcare Kingwood
  • CHI St. Luke's Health Memorial Livingston
  • Houston Methodist Clear Lake Hospital in Nassau Bay
  • HCA Houston Healthcare Pearland
  • Houston Methodist Sugar Land Hospital
  • CHI St. Luke's Health The Woodlands Hospital
  • Houston Methodist The Woodlands Hospital
  • Memorial Hermann The Woodlands Hospital
  • HCA Houston Healthcare Clear Lake in Webster

Skisak says the Leapfrog report card "is a valuable resource for employers to share with their employees so that they can self-navigate to the safest and highest quality hospitals."

"The Leapfrog Hospital Safety Grade offers critical patient safety information to consumers, in an easily digestible way, so that they can make informed decisions about where they seek care in the Houston area," he says in a release.

The Leapfrog Group bases its twice-a-year grades for hospital safety on 28 sets of publicly available data from more than 2,600 U.S. hospitals.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.